HOME >> BIOLOGY >> NEWS
Targeted Genetics presents clinical data on E1A cancer gene therapy

Phase II data and summary of Phase I studies presented at ASCO

New Orleans, LA-May 22, 2000-Targeted Genetics Corporation (Nasdaq: TGEN) yesterday presented data from its clinical studies of tgDCC-E1A, the Company's lead cancer therapy, at the 36th American Society of Clinical Oncology Annual Meeting in New Orleans, Louisiana. Dr. Thomas C. Reynolds, Vice President, Clinical Affairs at Targeted Genetics, presented data from clinical trials of tgDCC-E1A in patients with head and neck cancer or ovarian cancer at a poster discussion session on the topic of Biologic Therapy for cancer. Preclinical data from studies of a systemic delivery formulation of E1A also were presented in the same poster.

Data from a recently completed Phase II study of tgDCC-E1A in recurrent head and neck squamous cell carcinoma (HNSCC) were presented in an abstract titled "Activity of E1A in Human Clinical Trials." The Phase II study evaluated tgDCC-E1A as single-agent therapy in 24 patients with recurrent HNSCC. Patients received 30ug DNA/cm3 of tumor via intratumoral injection daily for three days and then weekly for seven weeks. The most common side effect was pain at the injection site, and no serious adverse events related to tgDCC-E1A were reported. Of 20 evaluable patients, 45% showed objective responses or stabilization of their disease as assessed by CT analysis. A 5% complete response rate also was observed by the same criteria. Tumor response was determined as a function of tumor growth measured by physical exam and by two-dimensional and three-dimensional CT analysis.

"These data suggest that tgDCC-E1A is safe and will be useful in the treatment of head and neck cancer," said Dr. Reynolds. "Although patients in this study had very advanced disease, we were able to generate a 45% response rate using tgDCC-E1A as a single agent. Preclinical studies show that E1A can sensitize tumors to radiation and chemotherapy and we believe that comb
'"/>

Contact: Page Sargisson
p.sargisson@noonanrusso.com
415-677-4455 x 229
Noonan/Russo Communications
21-May-2000


Page: 1 2 3

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted therapy for lung cancer patients shows promise in extending lives
3. Targeted immunotherapy eradicates cancer in mice
4. Targeted radiation to liver tumors spares tissue, improves quality of life
5. Targeted Genetics presents data on arthritis gene therapy
6. Targeted genetics presents promising data from cystic fibrosis clinical trial
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/15/2018)... ... September 14, 2018 , ... ... campaign will showcase the innovative work being done within rare diseases research, diagnostics, ... for those living with rare diseases. , The print component ...
(Date:9/12/2018)... ... September 11, 2018 , ... ... to introduce the new ChemXP™ line of high performance secondary containment coatings, designed ... developed to provide Tennant Coatings’ elite certified installers with the needed solutions to ...
(Date:9/12/2018)... ... September 12, 2018 , ... Captiva Spine, Inc., which ... has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to ... System. , TowerLOX-EXT MIS Extended Tab Pedicle Screws provide the narrow insertion of ...
Breaking Biology News(10 mins):
(Date:9/12/2018)... ... 2018 , ... Sterlitech Corporation, a global leader in custom ... Fluid Technology Solutions (FTS H2O) to their offering of filtration products. , ... (CTA) material. The highly hydrophilic nature of the CTA FO membranes favors proper ...
(Date:9/7/2018)... ... September 06, 2018 , ... ... neuromuscular disease, has been validated to be as effective as manual pathology. The ... Staining in Frozen Muscle Biopsies,” was published in the Archives of Pathology & ...
(Date:8/29/2018)... ... 2018 , ... Nanovis , an innovative and fast-growing ... a $5.5 million funding round managed by Commenda Securities. Key investors include Elevate ... Ventures. , “Our investment in Nanovis is consistent with our mission to support ...
(Date:8/29/2018)... ... August 28, 2018 , ... USDM Life Sciences , ... sciences and healthcare industries, announces that Manu Vohra will deliver a presentation at the ... “How to Implement Box for GxP in 30 Days” , When: Thursday, August ...
Breaking Biology Technology:
Cached News: